Ethylene

Ethylene

SCHEMBL6511634

C=C.O=C1CCn2c(Cl)nc3cccc1c32

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 12/20 0.42
KCNH2 Q12809 5/20 0.37
GRM2 Q14416 5/20 0.37
HTR3A P46098 1/20 0.35
HTR4 Q13639 1/20 0.34
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
USP2 O75604 1/20 0.33
NSD2 O96028 1/20 0.33
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33
CASP1 P29466 1/20 0.33
BRCA1 P38398 1/20 0.33
HTT P42858 1/20 0.33
CASP7 P55210 1/20 0.33
KMT2A Q03164 1/20 0.33
ATM Q13315 1/20 0.33
HSD17B10 Q99714 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6139222 0.97 PARP1 (0.44) PARP1KCNH2GRM2HTR3AHTR4
SCHEMBL6507233 0.88 PARP1 (0.42) PARP1KCNH2GRM2HTR3AHTR4
SCHEMBL8824023 0.78 PARP1 (0.68) PARP1KCNH2GRM2HTR3A
SCHEMBL2085916 0.77 PARP1 (0.42) PARP1KCNH2GRM2HTR3AKMT2A
SCHEMBL6199833 0.75 PARP1 (0.66) PARP1KCNH2GRM2HTR3A
SCHEMBL9675375 0.75 PARP1 (0.45) PARP1KCNH2GRM2HTR3AMAPT
SCHEMBL6139585 0.75 PARP1 (0.71) PARP1
SCHEMBL6829416 0.73 PARP1 (0.36) PARP1
SCHEMBL6514531 0.73 SMN1; SMN2 (0.32) PARP1
SCHEMBL7265551 0.73 ATM (0.45) PARP1KCNH2GRM2HTR3AUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050032779-A1 Benzimidazole derivatives, preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2005-02-10 US disclosed
US-6794382-B2 6-OXO-5,6-DIHYDRO-4H-IMIDAZO(4,5,1-IJ)QUINOLINE DERIVATIVES AS INHIBITORS OF ADP-RIBOSYLTRANSFERASE; CARDIOVASCULAR, IMMUNOLOGICAL, RESPIRATORY SYSTEM, AND NEURODEGENERATIVE DISORDER TREATMENT SANOFI-SYNTHELABO (FR) 2004-09-21 US disclosed
US-20030203893-A1 Benzimidazole derivatives, preparation and therapeutic use thereof SANOFI-AVENTIS (FR) 2003-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032779-A1 Benzimidazole derivatives, preparation and therapeutic use thereof CBR3, CYP3A7, HDAC7 PARP1 1406/4885KCNH2 520/4885GRM2 2906/4885
US-20030203893-A1 Benzimidazole derivatives, preparation and therapeutic use thereof CBR3, HRH4, CBR1 PARP1 1342/4885KCNH2 451/4885GRM2 1746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.